Shattuck Labs (STTK) Stock Overview
A clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
STTK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeShattuck Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.68 |
| 52 Week High | US$8.33 |
| 52 Week Low | US$0.71 |
| Beta | 1.19 |
| 1 Month Change | -1.47% |
| 3 Month Change | 87.11% |
| 1 Year Change | 665.70% |
| 3 Year Change | 139.43% |
| 5 Year Change | -75.93% |
| Change since IPO | -65.48% |
Recent News & Updates
Recent updates
Shutterstock: Surviving In An AI World Is Going To Be Tough
Mar 27Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?
Oct 02
Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation
Jun 15Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?
Jun 28We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
Mar 09Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?
Nov 23Shattuck Labs GAAP EPS of -$0.65 misses by $0.06
Aug 11We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
Jul 26Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 18Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?
Feb 25Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?
Nov 23Shareholder Returns
| STTK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.8% | 3.7% | 3.2% |
| 1Y | 665.7% | 41.9% | 31.0% |
Return vs Industry: STTK exceeded the US Biotechs industry which returned 39.2% over the past year.
Return vs Market: STTK exceeded the US Market which returned 29.8% over the past year.
Price Volatility
| STTK volatility | |
|---|---|
| STTK Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: STTK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: STTK's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 40 | Taylor Schreiber | www.shattucklabs.com |
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program.
Shattuck Labs, Inc. Fundamentals Summary
| STTK fundamental statistics | |
|---|---|
| Market cap | US$494.30m |
| Earnings (TTM) | -US$48.81m |
| Revenue (TTM) | US$1.00m |
Is STTK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STTK income statement (TTM) | |
|---|---|
| Revenue | US$1.00m |
| Cost of Revenue | US$2.95m |
| Gross Profit | -US$1.95m |
| Other Expenses | US$46.86m |
| Earnings | -US$48.81m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.65 |
| Gross Margin | -195.10% |
| Net Profit Margin | -4,880.90% |
| Debt/Equity Ratio | 0% |
How did STTK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/06 03:45 |
| End of Day Share Price | 2026/05/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shattuck Labs, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Yigal Nochomovitz | Citigroup Inc |
| Joseph Pantginis | H.C. Wainwright & Co. |